Hypotensive therapy in obstetric practice

Cover Page


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

Arterial hypertension remains a leading cause of maternal morbidity and mortality while leading to significant economic costs in health care. Properly selected treatment tactics allow for prolonging pregnancy and levelling out various complications arising from the disease. However, there are still some questions about the effectiveness and safety of prescribed therapy due to possible side effects of the drugs. The aim of this study was to evaluate the efficacy and complications of hypotensive therapy during pregnancy, childbirth and the postpartum period. We analyzed the literature on eLibrary, Scopus, Cochrane Library, PubMed.

Full Text

Restricted Access

About the authors

Aydar M. Ziganshin

Bashkir State Medical University

Author for correspondence.
Email: zigaidar@yandex.ru
ORCID iD: 0000-0001-5474-1080

MD, Dr. Sci. (Med.), Assistant Professor

Russian Federation, Ufa

Alina A. Maksyutova

Bashkir State Medical University

Email: alina.maxiutova@yandex.ru
ORCID iD: 0009-0001-4505-1683
Russian Federation, Ufa

References

  1. Federal State Institution “Scientific Center for Obstetrics, Gynecology and Perinatology named after Academician V.I. Kulakov” of the Ministry of Health and Economic Development of the Russian Federation, All-Russian Scientific Society of Cardiologists, Russian Medical Society for Arterial Hypertension. Diagnosis and treatment of arterial hypertension in pregnant women. Federal recommendations. 2018. Available from: https://moag.pro/wp-content/uploads/2014/10/5arter.pdf (In Russ.)
  2. Mravian SR, Petrukhin VA. Arterial hypertension in pregnant women. What, why and with what are we treating? Russian Bulletin of Obstetrician-Gynecologist. 2019;19(3):70-75. EDN: BEVIXW doi: 10.17116/rosakush20191903170
  3. Chulkov VS, Martynov AI, Kokorin VA. Arterial hypertension in pregnant women: debatable issues of national and international recommendations. Russian Journal of Cardiology. 2020;25(S4):41–81. EDN: UUFSBX doi: 10.15829/1560-4071-2020-4181
  4. Hasanova BM, Polina ML, Orazmuradov AA. The influence of cardiac phenotypes on the course and outcomes of pregnancy in hypertensive disorders. Obstetrics and gynecology: news, opinions, training. 2019;7(3):31–40. EDN: KNMPMU doi: 10.24411/2303-9698-2019-13904
  5. Shikh EV, Zhukova OV, Ostroumova OD, et al. Arterial hypertension in pregnant women: a view from the perspective of the European Recommendations of 2018. Arterial hypertension. 2019;25(1):105–115. EDN: ZEUODZ doi: 10.18705/1607-419X-2019-25-1-105-115
  6. Khedagi AM, Bello NA. Hypertensive disorders of pregnancy. Cardiol Clin. 2021;39(1):77–90. doi: 10.1016/j.ccl.2020.09.005
  7. Garovic VD, Dechend R, Easterling T, et al. Hypertension in pregnancy: diagnosis, blood pressure goals, and pharmacotherapy: a scientific statement from the american heart association. Hypertension. 2022;79(2):e21–e41. doi: 10.1161/HYP.0000000000000208
  8. Kirsanova TV. Principles of treatment of arterial hypertension during pregnancy. Russian Medical Journal. 2012;20(21):1097–1101. EDN: PMYTBD
  9. Gaisin IR, Iskhakova AS. Diagnosis and treatment of hypertensive disorders of pregnancy: a narrative review. Arterial hypertension. 2021;27(2):146–169. EDN: TRZMCA doi: 10.18705/1607-419X-2021-27-2-146-169
  10. ACOG Practice Bulletin № 202: gestational hypertension and preeclampsia. Obstet Gynecol. 2019;133(1):1. doi: 10.1097/AOG.0000000000003018
  11. Aylamazyan EK, Repina MA. Maternal mortality owing to eclampsia: what may do teach? Journal of Obstetrics and Women’s Diseases. 2013;62(3):3–8. EDN: RJMDOT doi: 10.17816/JOWD6233-8
  12. Madi JM, Araújo BF, Zatti H, et al. Chronic hypertension and pregnancy at a tertiary-care and university hospital. Hypertens Pregnancy. 2012;31(3):350–356. doi: 10.3109/10641955.2010.525279
  13. Rudakova IS, Shifman EM, Tikhnova GP, et al. Hypertensive disorders in pregnancy as a risk factor of premature placental abruption: a systematic review and meta-analysis. Russian Journal of Anesthesiology and Reanimatology. 2023;(2):6–14. EDN: ODAVMH doi: 10.17116/anaesthesiology20230216
  14. Kompaniets OG, Chernyakova NS, Babich AE, et al. Routine pharmacological treatment of essential hypertension in pregnant women: attention to details. Clinical analysis in obstetrics, gynecology and reproductology. 2021;3:5–12. EDN: GBAKUS doi: 10.47407/kragr2021.1.3.000017
  15. Cockburn J, Moar VA, Ounsted M, et al. Final report of study on hypertension during pregnancy: the effects of specific treatment on the growth and development of the children. Lancet. 1982;1(8273):647–649. doi: 10.1016/s0140-6736(82)92202-4
  16. Ostrov DA, Alkanani A, McDaniel KA, et al. Methyldopa blocks MHC class II binding to disease-specific antigens in autoimmune diabetes. J Clin Invest. 2018;128(5):1888–1902. doi: 10.1172/JCI97739
  17. Schubothe H, Maas D, Weber S, et al. Methyldopainduzierte autoimmunhämolytische Anämien. Verlaufs- und Langzeitbeobachtungen an 11 Patienten. Immun Infekt. 1982;10(6):230–239.
  18. Ostroumova OD, Bliznyuk SA, Kochetkov AI, et al. Drug-induced hemolytic anemia. Medical alphabet. 2021;(1):49–56. EDN: OCLJDQ doi: 10.33667/2078-5631-2021-1-49-56
  19. Ozsvár Z, Solymossi Z, Monostory K. Methyldopa-induced acute reactive hepatitis in pregnancy, drug-metabolizing capacity of the liver. Orv Hetil. 2010;151(11):457–461. doi: 10.1556/OH.2010.28736
  20. Filippova AV, Ostroumova OD. Drug-induced pancreatitis: focus on drugs used to treat diseases of the cardiovascular system. Medical Alphabet. 2021;(17):37–42. EDN: RZGZMH doi: 10.33667/2078-5631-2021-17-37-42
  21. Kernaghan D, Duncan AC, McKay GA. Hypertension in pregnancy: a review of therapeutic options. Obstet Med. 2012;5(2):44–49. doi: 10.1258/om.2011.110061
  22. Kuzmin OB, Zhezha VV. Refractory arterial hypertension: features of neurohormonal and water-salt balance and approaches to improving the effectiveness of drug therapy. Rational Pharmacotherapy in Cardiology. 2022;18(4):467–472. EDN: UYFJFV doi: 10.20996/1819-6446-2022-08-14
  23. Klimenchenko NI. Arterial hypertension and pregnancy. Obstetrics and gynecology. News. Opinions. Training. 2017;16(2):55–65. EDN: YPQBUX doi: 10.24411/2303-9698-2017-00032
  24. Ziganshin AM, Akbulatova EV. Tokolytics in obstetric practice. Journal of Obstetrics and Women’s Diseases. 2023;72(2):85–93. EDN: MTYQIK doi: 10.17816/JOWD115201
  25. Aylamazyan EK, Repina MA. The usual comment to clinical protocol “Hypertension during pregnancy, preeclampsia, eclampsia”. Journal of Obstetrics and Women’s Diseases. 2012;61(5):3–9. EDN: QBVSJJ doi: 10.17816/JOWD6153-9
  26. Akopov K, Zhukova E, Sokova E, et al. Analysis of the efficiency and safety of using the slow-release calcium channel blocker nifedipine as a tocolytic drug in pregnant women with preterm labor. Doctor. 2021;32(1):9–13. EDN: HLKZQL doi: 10.29296/25877305-2021-01-02
  27. Stryuk RI. The place of bisoprolol in the treatment of arterial hypertension in pregnant women. Medical alphabet. 2019;2(27):32–34. EDN: BNLPNF doi: 10.33667/2078-5631-2019-2-27(402)-32-34
  28. Easterling TR, Brateng D, Schmucker B, et al. Prevention of preeclampsia: a randomized trial of atenolol in hyperdynamic patients before onset of hypertension. Obstet Gynecol. 1999;93(5 Pt 1):725–733. doi: 10.1016/s0029-7844(98)00522-5
  29. Runikhina NK, Chukhareva NA, Klimenchenko NI, et al. New approaches in management of hypertension during pregnancy: limiting the use of beta-adrenergic blocking agents. Obstetrics and gynecology: news, opinions, training. 2014;6(4):88–94. EDN: WFVRZT
  30. von Dadelszen P., Ornstein M.P., Bull S.B., et al. Fall in mean arterial pressure and fetal growth restriction in pregnancy hypertension: a meta-analysis. Lancet. 2000;355(9198):87–92. doi: 10.1016/s0140-6736(98)08049-0
  31. Kasumova FN, Kasumova FZ, Mammadova RN, et al. The effect of long-term intake of nebivalol on the quality of life and adherence to treatment of patients with arterial hypertension. Cardiovascular therapy and prevention. 2019;18(S1):86. EDN: LUDNAO
  32. Pylaeva NYu, Shifman EM, Kulikov AV, et al. Preeclampsia. Eclampsia. Anesthesia and intensive care in childbirth and the puerperium. Review. Annals of Critical Care. 2020;(1):41–52. EDN: MMOOLT doi: 10.21320/1818-474X-2020-1-41-52
  33. Kosyakova OV, BESPALOVA ON. Prevention and therapy of threatening premature birth with multiple births. Journal of Obstetrics and Women’s Diseases. 2019;68(4):55–70. EDN: TLCJUV doi: 10.17816/JOWD68455-70
  34. Azria E, Tsatsaris V, Goffinet F, et al. Magnesium sulfate in obstetrics: current data. J Gynecol Obstet Biol Reprod (Paris). 2004;33(6 Pt 1):510–517. doi: 10.1016/s0368-2315(04)96564-7
  35. Gaisin IR, Iskhakova AS, Shamchuk ОP, et al. New approaches to classification, diagnosis and treatment of hypertensive disorders of pregnancy. health, demography, ecology of finno-ugric peoples. 2020;(4):27–35. EDN: NTQIXD
  36. Pascoal ACF, Katz L, Pinto MH, et al. Serum magnesium levels during magnesium sulfate infusion at 1 gram/hour versus 2 grams/hour as a maintenance dose to prevent eclampsia in women with severe preeclampsia: a randomized clinical trial. Medicine. 2019;98(32). doi: 10.1097/MD.0000000000016779
  37. Kryuchko DS, Shifman EM, Baibarina EN, et al. Impact of maternal magnesia therapy for preeclampsia on the newborn. Obstetrics and Gynecology. 2013;(5):23–29. EDN: QLHTBF
  38. Radzinsky VE, Orazmuradov AA, Savenkova IV, et al. Preterm labour: an open problem in XXI century. Kuban Scientific Medical Bulletin. 2020;27(4):27–37. EDN: IFKARF doi: 10.25207/1608-6228-2020-27-4-27-37
  39. Shatilova YuA, Zharkin NA, Yarygin OA, et al. Sovremennye aspekty v profilaktike i lechenii prezhdevremennykh rodov. Lekarstvennyy vestnik. 2018:12(3):14–18. EDN: YLWSXZ

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2024 Eсо-Vector


СМИ зарегистрировано Федеральной службой по надзору в сфере связи, информационных технологий и массовых коммуникаций (Роскомнадзор).
Регистрационный номер и дата принятия решения о регистрации СМИ: серия ПИ № ФС 77 - 66759 от 08.08.2016 г. 
СМИ зарегистрировано Федеральной службой по надзору в сфере связи, информационных технологий и массовых коммуникаций (Роскомнадзор).
Регистрационный номер и дата принятия решения о регистрации СМИ: серия Эл № 77 - 6389 от 15.07.2002 г.


This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies